CD44 and cancer: The high anticancer efficiency of PCLP-CUR might be due to the following reasons: the entrapment of CUR inside of the PCLP-CUR improved its in vivo retention time, bioavailability and tumor specificity, which allowed more drug accumulation at the cancerous site; platelet membrane camouflage contributed to the increasing uptake of CUR by cancer cells through interaction between P-selectin and CD44 [42]; and the modification of chitosan accelerated drug release at the tumor regions [35].